Search 

Horizon Technology Finance is a venture lending, investment and financial services management company that was founded in 2003 and is headquartered in Farmington, Ct with additional offices in Walnut Creek, CA and Reston, VA. The firm controls approximately $200 million in assets under management and look to provide senior or subordinate loans to companies in the range of $2 to $20 million dollars, and often syndicates much larger deals. The firm prefers to lead or co-lead investments that they are involved in and looks to be involved in 15 deals in the next 6-9 months. The firm provides capital to companies located throughout the United States and Canada.

Immusoft’s mission is to develop a breakthrough platform for delivering targeted medicines — programming a patient’s own cells to become miniature drug factories.

Our technology instructs a patient's cells to constantly secrete gene-encoded medicines (biologics). It will enable new treatments by solving current delivery limitations and production challenges. We are initially targeting orphaned diseases. 

Immusoft’s platform can program cells to continually produce and secrete therapeutic proteins and rare antibodies that have been impossible to elicit with a vaccine. This approach makes possible treatments that are otherwise impractical due to short halflife, injection site reactions, production challenges or a small market size. It offers many of the benefits of traditional approaches and modern gene therapies with less risk and greater control.

Immusoft has received grants from the National Institutes of Health and Peter Thiel's Breakout Labs as well as support from private investors, including the former head of preclinical development at Seattle Genetics. We have an exclusive license option on our core technology from Caltech and have filed two additional patents covering our extensive modifications to the technology.

ISP technology could replace a lifetime of infusions with a patient’s own drug-producing cells.

Joslin Diabetes Center is a foundation based in Boston, Massachusetts that was founded in 1898, and is the world's largest diabetes and clinical care organization.

Kineta® is a nationally-recognized biotechnology company focused on developing leading edge therapeutics in three large high need therapeutic areas: autoimmune disease, viral disease and chronic pain. Our company is focused on the development of novel drug candidates each the outcome of years of scientific exploration and supported by an extensive body of peer-reviewed NIH-supported research.